ArticleACS omega2026
Chlorin e6-Based Photodynamic Therapy for Metastatic Melanoma: An
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma, the most aggressive form of skin cancer, remains incurable despite advances in treatment. Therefore, the need for alternative treatment approaches remains high. Photodynamic therapy is a localized, noninvasive treatment method. A photosensitizer is a crucial component of photodynamic therapy (PDT), which generates cytotoxic reactive oxygen species to kill cancer cells. A second-generation photosensitizer with FDA approval that satisfies the necessary clinical requirements for PDT is Chlorin e6 (Ce6). It is well-known for its strong anticancer effects on various cancer types and for its significant capacity to produce reactive oxygen species (ROS). Ce6 has demonstrated significant therapeutic potential against various cancers, including refractory ovarian, lung, melanoma, and metastatic breast cancer. In this study, we investigated the
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.